For the management of nausea and vomiting, and dizziness associated with motion sickness.
Dosage and administration
Motion Sickness The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
Chemically, Meclizine HCl is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.
Structure of Meclizine HCl
Meclizine HCI Tablets, USP are available in two different strengths: 12.5 mg and
25 mg. In addition each tablet contains the following inactive ingredients:
Colloidal Silicon Dioxide, Croscarmellose Sodium, Lactose Monohydrate, Magnesium
Stearate, Microcrystalline Cellulose. Also, Meclizine HCI Tablets USP, 12.5 mg
contains FD&C Blue #1 Aluminum Lake (11-13%) and Meclizine HCI Tablets USP,
25 mg contains D&C Yellow #10 Aluminum Lake (15-20%).
CLINICAL PHARMACOLOGY
CLINICAL PHARMACOLOGY SECTION
Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.
INDICATIONS AND USAGE
INDICATIONS & USAGE SECTION
For the management of nausea and vomiting, and dizziness associated with motion sickness.
CONTRAINDICATIONS
CONTRAINDICATIONS SECTION
Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.
WARNINGS
WARNINGS SECTION
Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.
Patients should avoid alcoholic beverages while taking this drug.
Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.
PRECAUTIONS
PRECAUTIONS SECTION
PREGNANCY, Teratogenic Effects Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that medicine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary. Pediatric Use Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.
ADVERSE REACTIONS
ADVERSE REACTIONS SECTION
Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.
DOSAGE AND ADMINISTRATION
DOSAGE & ADMINISTRATION SECTION
Motion Sickness The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
HOW SUPPLIED
HOW SUPPLIED SECTION
Meclizine HCI Tablets, USP are available in the following strengths and package sizes:
12.5 mg (Blue, oval-shaped, scored, debossed with TL122)
Bottles of 100 NDC 59746-122-06 Bottles of 1000 NDC 59746-122-10
25 mg (Yellow, oval-shaped, scored, debossed with TL121)
Bottles of 100 NDC 59746-121-06 Bottles of 1000 NDC 59746-121-10
Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature].
Manufactured By:
Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
